Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

G1 Therapeutics' PRESERVE 2 Phase 3 Trial Of Trilaciclib Before First Line Chemotherapy in Metastatic Triple Negative Breast Cancer Did Not Achieve Statistical Significance In Primary Endpoint of Overall Survival

Author: Benzinga Newsdesk | June 24, 2024 05:34am

The Company Will Focus its Efforts on the Global Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market.
G1 is Sufficiently Funded to Achieve Anticipated Company Profitability in the Second Half of 2025.

Posted In: GTHX